Cyclacel Phar Pr Stock Price, News & Analysis

Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced the publication of preclinical data demonstrating the effectiveness of their drug plogosertib in treating fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer affecting young people with no approved treatments.

The study, published in the journal Gut, revealed that FLC cells are highly sensitive to PLK1 inhibition by plogosertib. The research showed that the DNAJ-PKAc fusion oncoprotein, which drives FLC progression, interacts with PLK1 at the centrosome. Notably, plogosertib demonstrated significant reduction in FLC growth while sparing normal liver cells in both in vitro and in vivo models.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has amended its Exchange Agreement with FITTERS Diversified Berhad. The amended agreement includes a new cash consideration of $1 million in addition to the previously agreed stock exchange and extends the final date to September 30, 2025.

Under the Transaction, Cyclacel will acquire all ordinary shares of Fitters Sdn. Bhd., making it a wholly-owned subsidiary, in exchange for Cyclacel common stock representing 19.99% of outstanding shares. The deal requires approval from both companies' stockholders and has received unanimous board approval from all parties involved.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-15 reverse stock split effective July 7, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L876.

Following the split, every 15 shares will automatically convert into one share, with fractional shares being rounded up or down. The total number of outstanding shares will decrease from 23,759,475 to 1,583,965. The reverse split, approved by both the board and stockholders, will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has secured $3 million in gross proceeds through a private placement of convertible Series F Preferred Stock to accredited investors. The company issued three series of warrants (A, B, and C) to purchase 3,270,000 shares each of common stock at exercise prices of $0.51, $0.60, and $0.68 respectively, with a 5-year expiration. Each preferred share is convertible into 3.27 common shares, subject to stockholder approval. The financing, combined with existing cash, is expected to extend Cyclacel's runway into Q3 2025. The proceeds will be used for working capital and general corporate purposes. The securities were issued under Regulation S and have not been registered under the Securities Act of 1933.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq's Listing Qualifications Department on June 3, 2025, stating that it has met the minimum $1.00 bid price requirement for 15 consecutive business days, from May 12 to June 2, 2025. This development resolves the previous non-compliance notification received on December 6, 2024, when CYCC's stock failed to maintain the required minimum bid price. The matter is now considered closed, allowing Cyclacel, a biopharmaceutical company focused on innovative cancer medicine development, to maintain its Nasdaq listing.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported Q1 2025 financial results and announced strategic changes. The company will now focus solely on developing plogosertib (plogo), having repurchased related assets for $0.3M. Following the liquidation of UK subsidiary Cyclacel Limited on January 31, 2025, the company deconsolidated its financials, resulting in a $5.0M gain in stockholders' equity. Due to funding challenges, Cyclacel entered an Exchange Agreement with FITTERS Diversified Berhad, exchanging shares for approximately 19.99% ownership to acquire Fitters Sdn. Bhd., a Malaysian fire safety equipment company. Q1 2025 financials show cash position of $3.5M, reduced R&D expenses of $0.8M (vs $2.8M in Q1 2024), increased G&A expenses of $4.2M, and a minimal net loss of $0.1M. Current cash is expected to fund operations into Q2 2025.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-16 reverse stock split effective May 12, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L884.

Following the split, every 16 shares will automatically convert into one share, with fractional shares being rounded up or down. The pre-split share count of 356,357,531 will be reduced to 22,272,346 post-split. The reverse split was approved by both the board of directors and stockholders, and will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has entered into an Exchange Agreement with FITTERS Diversified Berhad to acquire its subsidiary, Fitters Sdn. Bhd., through a share exchange transaction. Under the agreement, Cyclacel will issue common stock representing 19.99% of its outstanding shares to FITTERS, while existing Cyclacel stockholders will retain approximately 80.01% ownership of the combined company.

Post-transaction, Cyclacel will be renamed to Bio Green Med Solution, Inc. and will continue trading on Nasdaq under a new ticker symbol. The deal must close by August 31, 2025, and requires approval from both companies' stockholders. The transaction has already received unanimous approval from the Boards of Directors of all involved entities. No officers or directors from FITTERS or Fitters Sub will be appointed to Cyclacel.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced its Q4 2024 financial results and strategic updates. The company is streamlining operations to focus on developing plogosertib, a PLK 1 inhibitor for advanced cancers, following its acquisition from Cyclacel on March 10, 2025.

Financial highlights include:

• Pro forma cash and equivalents of $7.2M as of Dec 31, 2024
• R&D expenses decreased to $6.7M in 2024 from $19.2M in 2023
• Net loss reduced to $11.2M in 2024 from $22.6M in 2023
• Current cash expected to fund operations into Q2 2025

The liquidation of Cyclacel is expected to increase stockholders' equity by approximately $5.0M and significantly reduce R&D expenses in 2025. The company is developing a new oral formulation of plogosertib with improved bioavailability.